# Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
Canonical URL: https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-to-host-first-quarter-2026-financial-results-conference-cal-42a5e6f1
Ticker: FULC
Company: Fulcrum Therapeutics
Source: Fulcrum Therapeutics
Published: 2026-04-20 12:00 EST
## Summary

Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical...

## Article Body
Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2026 financial results will be released on Monday, April 27, 2026, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Individuals may register for the conference call by clicking the link here . Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here . Following the live webcast, an archived replay will also be available.

About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on the development of small molecule therapies that improve the lives of people with rare hematological disorders. The company’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.

Contact: Kevin Gardner LifeSci Advisors, LLC kgardner@lifesciadvisors.com 617-283-2856
## Recent Company News
- 2026-06-01 20:05 EST — [Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-discontinuation-of-pociredir-program-in-sickle-ce-a4687a0d) — Source: Fulcrum Therapeutics
- 2026-05-08 20:30 EST — [Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--af9b71b6) — Source: Fulcrum Therapeutics
- 2026-04-27 11:00 EST — [Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results--b3f1692d) — Source: Fulcrum Therapeutics
- 2026-04-27 10:55 EST — [Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-appoints-josh-lehrer-to-its-board-of-directors-6c29e5a6) — Source: Fulcrum Therapeutics
- 2026-04-20 12:00 EST — [Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-to-host-first-quarter-2026-financial-results-conference-cal-42a5e6f1) — Source: Fulcrum Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)